Silence Financial Statements From 2010 to 2025

SLN Stock  USD 5.04  0.34  6.32%   
Silence Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Silence Therapeutics' valuation are provided below:
Gross Profit
18.6 M
Profit Margin
(2.58)
Market Capitalization
238.7 M
Enterprise Value Revenue
3.7644
Revenue
27.7 M
We have found one hundred twenty available fundamental trend indicators for Silence Therapeutics PLC, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Silence Therapeutics' current fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 10th of August 2025, Market Cap is likely to grow to about 1 B. Also, Enterprise Value is likely to grow to about 896.2 M

Silence Therapeutics Total Revenue

45.42 Million

Check Silence Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Silence Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 622.6 K, Interest Expense of 29.1 K or Other Operating Expenses of 111.9 M, as well as many indicators such as Price To Sales Ratio of 7.14, Dividend Yield of 0.0 or PTB Ratio of 2.3. Silence financial statements analysis is a perfect complement when working with Silence Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Silence Stock
Check out the analysis of Silence Therapeutics Correlation against competitors.

Silence Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets212.8 M202.6 M73.1 M
Slightly volatile
Other Current Liabilities12.4 M11.8 M5.2 M
Slightly volatile
Total Current Liabilities17.7 M16.8 M8.8 M
Slightly volatile
Total Stockholder Equity140.7 M134 M41.3 M
Slightly volatile
Property Plant And Equipment Net2.1 MM1.1 M
Slightly volatile
Accounts Payable3.9 M3.7 M1.8 M
Slightly volatile
Cash127.4 M121.3 M42.1 M
Slightly volatile
Non Current Assets Total8.5 M15.3 M10.6 M
Very volatile
Cash And Short Term Investments154.7 M147.3 M49.3 M
Slightly volatile
Common Stock Total EquityM4.8 M3.6 M
Slightly volatile
Common Stock Shares Outstanding49.6 M47.2 M23.8 M
Slightly volatile
Liabilities And Stockholders Equity212.8 M202.6 M73.1 M
Slightly volatile
Non Current Liabilities Total54.4 M51.8 M23.3 M
Slightly volatile
Other Current Assets55.8 M53.2 M9.2 M
Slightly volatile
Total Liabilities72 M68.6 M31.8 M
Slightly volatile
Property Plant And Equipment Gross7.2 M6.9 M2.4 M
Slightly volatile
Total Current Assets196.7 M187.4 M62 M
Slightly volatile
Common Stock7.2 M6.8 MM
Slightly volatile
Net Receivables28.3 M26.9 M7.6 M
Slightly volatile
Good Will7.8 M9.4 MM
Pretty Stable
Intangible Assets310.5 K312 K254.5 K
Slightly volatile
Current Deferred Revenue290.7 K306 K3.1 M
Slightly volatile
Short Term Debt111.2 K117 K503.1 K
Slightly volatile
Net Tangible Assets16.7 M12.4 M29.2 M
Slightly volatile
Other Assets187.6 K209.7 K230 K
Slightly volatile
Property Plant Equipment1.5 M2.5 M1.5 M
Slightly volatile
Net Invested Capital140.7 M134 M50.4 M
Pretty Stable
Net Working Capital179.1 M170.5 M62.9 M
Slightly volatile
Capital Stock5.9 M10.3 M4.5 M
Slightly volatile
Short and Long Term Debt Total213.3 K117 K274.8 K
Pretty Stable
Other Liabilities55.8 M73 M33.4 M
Slightly volatile
Capital Lease Obligations213.3 K117 K274.8 K
Pretty Stable
Long Term Investments234.4 K255.6 K293.2 K
Slightly volatile

Silence Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization622.6 K593 K382 K
Slightly volatile
Interest Expense29.1 K30.6 K153.8 K
Pretty Stable
Other Operating Expenses111.9 M106.6 M35.9 M
Slightly volatile
Research Development71.3 M67.9 M21.2 M
Slightly volatile
Total Operating Expenses99.5 M94.8 M32.1 M
Slightly volatile
Selling General Administrative28.2 M26.9 M11 M
Slightly volatile
Cost Of Revenue7.9 M11.8 M7.2 M
Slightly volatile
Reconciled Depreciation523.9 K593 K460.3 K
Slightly volatile

Silence Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation277 K336 K344.3 K
Slightly volatile
Capital Expenditures262.1 K211 K344.9 K
Pretty Stable
End Period Cash Flow127.4 M121.3 M42.1 M
Slightly volatile
Begin Period Cash Flow72.2 M68.8 M32.2 M
Slightly volatile
Stock Based Compensation17.1 M16.3 M4.8 M
Slightly volatile
Issuance Of Capital Stock149.2 M142.1 M25.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.147.51092.6 K
Pretty Stable
PTB Ratio2.32.424314.2918
Slightly volatile
Days Sales Outstanding2162271.3 K
Very volatile
Book Value Per Share2.72.8383.6594
Slightly volatile
Stock Based Compensation To Revenue0.360.3778.9268
Pretty Stable
Capex To Depreciation0.780.6281.2439
Pretty Stable
PB Ratio2.32.424314.2918
Slightly volatile
EV To Sales18.7419.73067.5 K
Pretty Stable
Payables Turnover3.033.194510.6922
Slightly volatile
Sales General And Administrative To Revenue0.590.621525.2547
Pretty Stable
Research And Ddevelopement To Revenue1.491.569382.2184
Pretty Stable
Capex To Revenue0.00460.00492.3682
Pretty Stable
Cash Per Share2.963.11992.4213
Pretty Stable
Days Payables Outstanding12011483.3102
Slightly volatile
Intangibles To Total Assets0.04550.04790.2167
Slightly volatile
Net Debt To EBITDA2.712.47432.5004
Very volatile
Current Ratio7.7711.138211.5855
Pretty Stable
Tangible Book Value Per Share2.52.63252.7413
Slightly volatile
Receivables Turnover1.531.60769.0449
Pretty Stable
Shareholders Equity Per Share2.72.8383.6594
Slightly volatile
Debt To Equity8.0E-49.0E-40.0143
Pretty Stable
Capex Per Share0.00420.00450.0209
Slightly volatile
Revenue Per Share0.870.9160.3483
Pretty Stable
Debt To Assets5.0E-46.0E-40.0047
Slightly volatile
Price Book Value Ratio2.32.424314.2918
Slightly volatile
Days Of Payables Outstanding12011483.3102
Slightly volatile
Ebt Per Ebit0.730.70220.9023
Pretty Stable
Company Equity Multiplier1.641.51192.8783
Slightly volatile
Total Debt To Capitalization8.0E-49.0E-40.014
Pretty Stable
Debt Equity Ratio8.0E-49.0E-40.0143
Pretty Stable
Quick Ratio7.9311.138211.9803
Pretty Stable
Net Income Per E B T0.971.0190.8707
Very volatile
Cash Ratio6.697.21269.5685
Pretty Stable
Days Of Sales Outstanding2162271.3 K
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00311.0206
Pretty Stable
Price To Book Ratio2.32.424314.2918
Slightly volatile
Fixed Asset Turnover22.9621.902826.6989
Slightly volatile
Debt Ratio5.0E-46.0E-40.0047
Slightly volatile
Price Sales Ratio7.147.51092.6 K
Pretty Stable
Asset Turnover0.220.21350.0741
Slightly volatile
Price Fair Value2.32.424314.2918
Slightly volatile

Silence Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapB974.7 M891.3 M
Slightly volatile
Enterprise Value896.2 M853.5 M849.3 M
Slightly volatile

Silence Fundamental Market Drivers

Cash And Short Term Investments147.3 M

Silence Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Silence Therapeutics Financial Statements

Silence Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Silence Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue306 K290.7 K
Total Revenue43.3 M45.4 M
Cost Of Revenue11.8 M7.9 M
Stock Based Compensation To Revenue 0.38  0.36 
Sales General And Administrative To Revenue 0.62  0.59 
Research And Ddevelopement To Revenue 1.57  1.49 
Revenue Per Share 0.92  0.87 
Ebit Per Revenue(1.46)(1.54)

Pair Trading with Silence Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Silence Stock

  0.65MRK Merck CompanyPairCorr

Moving against Silence Stock

  0.38IKT Inhibikase TherapeuticsPairCorr
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Silence Therapeutics PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Silence Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Silence Therapeutics Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Silence Therapeutics Plc Stock:
Check out the analysis of Silence Therapeutics Correlation against competitors.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.68)
Revenue Per Share
0.589
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.21)
Return On Equity
(0.53)
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.